Assessment
lorlatinib
ALK-positive, advanced non-small cell lung cancer (NSCLC), previously untreated with an ALK inhibitor
- Modules
- IQWiG assessments · G-BA decisions
- Connections
- 2
Connected evidence
2 relationsAssessment
ALK-positive, advanced non-small cell lung cancer (NSCLC), previously untreated with an ALK inhibitor
Connected evidence
2 relations